These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 33187074)

  • 1. Spike Glycoprotein-Mediated Entry of SARS Coronaviruses.
    Wang L; Xiang Y
    Viruses; 2020 Nov; 12(11):. PubMed ID: 33187074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Receptor utilization of angiotensin-converting enzyme 2 (ACE2) indicates a narrower host range of SARS-CoV-2 than that of SARS-CoV.
    Wang Q; Qiu Y; Li JY; Liao CH; Zhou ZJ; Ge XY
    Transbound Emerg Dis; 2021 May; 68(3):1046-1053. PubMed ID: 32794346
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Lapaillerie D; Charlier C; Fernandes HS; Sousa SF; Lesbats P; Weigel P; Favereaux A; Guyonnet-Duperat V; Parissi V
    Viruses; 2021 Feb; 13(3):. PubMed ID: 33669132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spike glycoproteins: Their significance for corona viruses and receptor binding activities for pathogenesis and viral survival.
    Noman A; Aqeel M; Khalid N; Hashem M; Alamari S; Zafar S; Qasim M; Irshad MK; Qari SH
    Microb Pathog; 2021 Jan; 150():104719. PubMed ID: 33373693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of Human ACE2 to Membrane-Bound SARS-CoV-1 and SARS-CoV-2 S Glycoproteins.
    Anand SP; Chen Y; Prévost J; Gasser R; Beaudoin-Bussières G; Abrams CF; Pazgier M; Finzi A
    Viruses; 2020 Sep; 12(10):. PubMed ID: 33003587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Why are ACE2 binding coronavirus strains SARS-CoV/SARS-CoV-2 wild and NL63 mild?
    Rawat P; Jemimah S; Ponnuswamy PK; Gromiha MM
    Proteins; 2021 Apr; 89(4):389-398. PubMed ID: 33210300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
    Hoffmann M; Kleine-Weber H; Schroeder S; Krüger N; Herrler T; Erichsen S; Schiergens TS; Herrler G; Wu NH; Nitsche A; Müller MA; Drosten C; Pöhlmann S
    Cell; 2020 Apr; 181(2):271-280.e8. PubMed ID: 32142651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and Antibodies.
    Papageorgiou AC; Mohsin I
    Cells; 2020 Oct; 9(11):. PubMed ID: 33105869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
    Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19.
    Kuba K; Yamaguchi T; Penninger JM
    Front Immunol; 2021; 12():732690. PubMed ID: 35003058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Feasible Alternative Strategy Targeting Furin Disrupts SARS-CoV-2 Infection Cycle.
    Mondal T; Shivange G; Habieb A; Tushir-Singh J
    Microbiol Spectr; 2022 Feb; 10(1):e0236421. PubMed ID: 35138160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamics of SARS-CoV-2 Spike Proteins in Cell Entry: Control Elements in the Amino-Terminal Domains.
    Qing E; Kicmal T; Kumar B; Hawkins GM; Timm E; Perlman S; Gallagher T
    mBio; 2021 Aug; 12(4):e0159021. PubMed ID: 34340537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonmuscle myosin heavy chain IIA facilitates SARS-CoV-2 infection in human pulmonary cells.
    Chen J; Fan J; Chen Z; Zhang M; Peng H; Liu J; Ding L; Liu M; Zhao C; Zhao P; Zhang S; Zhang X; Xu J
    Proc Natl Acad Sci U S A; 2021 Dec; 118(50):. PubMed ID: 34873039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein structure analysis of the interactions between SARS-CoV-2 spike protein and the human ACE2 receptor: from conformational changes to novel neutralizing antibodies.
    Mercurio I; Tragni V; Busto F; De Grassi A; Pierri CL
    Cell Mol Life Sci; 2021 Feb; 78(4):1501-1522. PubMed ID: 32623480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The expression of hACE2 receptor protein and its involvement in SARS-CoV-2 entry, pathogenesis, and its application as potential therapeutic target.
    Al-Zaidan L; Mestiri S; Raza A; Merhi M; Inchakalody VP; Fernandes Q; Taib N; Uddin S; Dermime S
    Tumour Biol; 2021; 43(1):177-196. PubMed ID: 34420993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.
    Yi C; Sun X; Ye J; Ding L; Liu M; Yang Z; Lu X; Zhang Y; Ma L; Gu W; Qu A; Xu J; Shi Z; Ling Z; Sun B
    Cell Mol Immunol; 2020 Jun; 17(6):621-630. PubMed ID: 32415260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural basis of severe acute respiratory syndrome coronavirus 2 infection.
    Ge J; Zhang S; Zhang L; Wang X
    Curr Opin HIV AIDS; 2021 Jan; 16(1):74-81. PubMed ID: 33186231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Possible inhibition of GM-CSF production by SARS-CoV-2 spike-based vaccines.
    Li J; Wang P; Tracey KJ; Wang H
    Mol Med; 2021 May; 27(1):49. PubMed ID: 34022793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamics of the ACE2-SARS-CoV-2/SARS-CoV spike protein interface reveal unique mechanisms.
    Ali A; Vijayan R
    Sci Rep; 2020 Aug; 10(1):14214. PubMed ID: 32848162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Critical ACE2 Determinants of SARS-CoV-2 and Group 2B Coronavirus Infection and Replication.
    Adams LE; Dinnon KH; Hou YJ; Sheahan TP; Heise MT; Baric RS
    mBio; 2021 Mar; 12(2):. PubMed ID: 33727353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.